Deusdedit Brandão Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deusdedit Brandão Neto has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Richard Louis Voegels
Department of Otorhinolaryngology, Universidade de São Paulo, São Paulo, SP, Brazil
6 shared publications - Fábio de Rezende Pinna
Department of Otorhinolaryngology, Universidade de São Paulo, São Paulo, SP, Brazil
5 shared publications Fabio de Rezende Pinna
Department of Otorhinolaryngology University of São Paulo São Paulo Brazil
2 shared publications- Mariana Ferreira Sbrana
Department of Otorhinolaryngology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
2 shared publications - Renata Ferraz Rafael Borges
Universidade de São Paulo (USP), Departamento de Otorrinolaringologia, São Paulo, SP, Brazil
2 shared publications - Adriana Ladeira de Araújo
Diretoria Executiva dos LIMs, Faculdade de Medicina da Universidade de São Paulo HCFMUSP, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 25 May 2024
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 28 (04) , e592-e596
Assessment of the Use of Telemedicine by Brazilian Otolaryngologists through an Online Questionnaire
Introduction The coronavirus disease 2019 (COVID-19) pandemic has prompted a transformation in medical practice, including the adoption of telemedicine in Brazil and globally. Otorhinolaryngology, a field at high risk of viral transmission, has witnessed an increasing use of telemedicine tools. However, the extent and challenges of telemedicine in this field in Brazil are not well understood. In the present study, we applied a questionnaire to Brazilian otorhinolaryngologists during the pandemic to assess telemedicine's advantages and challenges, shedding light on its integration and persistent issues in the field. Objective To assess the usage profile of telemedicine in the clinical practice of otolaryngology in Brazil. Methods The present was a cross-sectional observational study with convenience sampling. It was conducted as a web-based questionnaire distributed and advertised to Brazilian otorhinolaryngologists through social media posts on WhatsApp (Meta Platforms, Inc., Menlo Park, CA, USA), Instagram (Meta Platforms, Inc.), Facebook (Meta Platforms, Inc.), as well as direct messaging and email. Results The sample size was 186 participants. A total of 69% of them had already provided or were currently providing telemedicine services, and 34% considered it a frequent or very frequent form of work at the time of data collection. In total, 90% of the respondents considered the lack of physical examination a problem in otolaryngological teleconsultations, while 64% reported frequently or very frequently resolving patient problems through teleconsultations. Conclusion Telemedicine emerged in the context of the COVID-19 pandemic as a promising tool for remote patient care. More studies are needed to elucidate its role in the context of limited physical examination.
- 25 May 2024
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 28 (04) , e592-e596
Open AccessAssessment of the Use of Telemedicine by Brazilian Otolaryngologists through an Online Questionnaire
Introduction The coronavirus disease 2019 (COVID-19) pandemic has prompted a transformation in medical practice, including the adoption of telemedicine in Brazil and globally. Otorhinolaryngology, a field at high risk of viral transmission, has witnessed an increasing use of telemedicine tools. However, the extent and challenges of telemedicine in this field in Brazil are not well understood. In the present study, we applied a questionnaire to Brazilian otorhinolaryngologists during the pandemic to assess telemedicine's advantages and challenges, shedding light on its integration and persistent issues in the field. Objective To assess the usage profile of telemedicine in the clinical practice of otolaryngology in Brazil. Methods The present was a cross-sectional observational study with convenience sampling. It was conducted as a web-based questionnaire distributed and advertised to Brazilian otorhinolaryngologists through social media posts on WhatsApp (Meta Platforms, Inc., Menlo Park, CA, USA), Instagram (Meta Platforms, Inc.), Facebook (Meta Platforms, Inc.), as well as direct messaging and email. Results The sample size was 186 participants. A total of 69% of them had already provided or were currently providing telemedicine services, and 34% considered it a frequent or very frequent form of work at the time of data collection. In total, 90% of the respondents considered the lack of physical examination a problem in otolaryngological teleconsultations, while 64% reported frequently or very frequently resolving patient problems through teleconsultations. Conclusion Telemedicine emerged in the context of the COVID-19 pandemic as a promising tool for remote patient care. More studies are needed to elucidate its role in the context of limited physical examination.
- Open Access
- 28 May 2022
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 273 (2) , 325-333
Association between chemosensory impairment with neuropsychiatric morbidity in post-acute COVID-19 syndrome: results from a multidisciplinary cohort study
Preliminary methodologically limited studies suggested that taste and smell known as chemosensory impairments and neuropsychiatric symptoms are associated in post-COVID-19. The objective of this study is to evaluate whether chemosensory dysfunction and neuropsychiatric impairments in a well-characterized post-COVID-19 sample. This is a cohort study assessing adult patients hospitalized due to moderate or severe forms of COVID-19 between March and August 2020. Baseline information includes several clinical and hospitalization data. Further evaluations were made using several different reliable instruments designed to assess taste and smell functions, parosmia, and neuropsychiatric disorders (using standardized psychiatric and cognitive measures). Out of 1800 eligible individuals, 701 volunteers were assessed on this study. After multivariate analysis, patients reporting parosmia had a worse perception of memory performance (p < 0.001). Moderate/severe hypogeusia was significantly associated with a worse performance on the word list memory task (p = 0.012); Concomitant moderate/severe olfactory and gustatory loss during the acute phase of COVID-19 was also significantly associated with episodic memory impairment (p = 0.006). We found a positive association between reported chemosensory (taste and olfaction) abnormalities and cognition dysfunction in post-COVID-19 patients. These findings may help us identify potential mechanisms linking these two neurobiological functions, and also support the speculation on a possible route through which SARS-CoV-2 may reach the central nervous system.
- 28 May 2022
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 273 (2) , 325-333
Open AccessAssociation between chemosensory impairment with neuropsychiatric morbidity in post-acute COVID-19 syndrome: results from a multidisciplinary cohort study
Preliminary methodologically limited studies suggested that taste and smell known as chemosensory impairments and neuropsychiatric symptoms are associated in post-COVID-19. The objective of this study is to evaluate whether chemosensory dysfunction and neuropsychiatric impairments in a well-characterized post-COVID-19 sample. This is a cohort study assessing adult patients hospitalized due to moderate or severe forms of COVID-19 between March and August 2020. Baseline information includes several clinical and hospitalization data. Further evaluations were made using several different reliable instruments designed to assess taste and smell functions, parosmia, and neuropsychiatric disorders (using standardized psychiatric and cognitive measures). Out of 1800 eligible individuals, 701 volunteers were assessed on this study. After multivariate analysis, patients reporting parosmia had a worse perception of memory performance (p < 0.001). Moderate/severe hypogeusia was significantly associated with a worse performance on the word list memory task (p = 0.012); Concomitant moderate/severe olfactory and gustatory loss during the acute phase of COVID-19 was also significantly associated with episodic memory impairment (p = 0.006). We found a positive association between reported chemosensory (taste and olfaction) abnormalities and cognition dysfunction in post-COVID-19 patients. These findings may help us identify potential mechanisms linking these two neurobiological functions, and also support the speculation on a possible route through which SARS-CoV-2 may reach the central nervous system.
- Open Access
- 29 October 2021
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 25 (04) , e479-e480
COVID-19 and Anosmia: Remaining Gaps to Knowledge
Since the emergence of the first cases of Sars-Cov-2 infection in November 2019, more than 224 million people have tested positive for COVID-19, and of these, more than 4.6 million have lost their lives worldwide.[1] Despite the rapid development of several types of vaccines that allowed a decrease in the rise of the number of new cases and deaths, the end of this story does not seem so close since fully vaccinated patients can also be infected. The virus has undergone constant mutations that sometimes produce milder symptoms and less resistance, sometimes manifest themselves more aggressively and with greater transmissibility. The olfactory disturbances in COVID-19 patients have drawn worldwide attention to an extremely important and often neglected sense. Smell plays a fundamental role in our lives, both for safety reasons as detecting odors of burning, gas leak or spoiled food, as well as in the quality of life by providing us with pleasure while eating, in interpersonal relationships, and also preventing us from hygiene issues. Despite the fact that there is no consensus regarding the exact pathophysiological mechanism, prevalence, and recovery of olfactory disorders in COVID-19, there is still a lot to understand about the persistent changes and how to intervene for adequate recovery of these patients. The olfactory neuroepithelium expresses receptors for the angiotensin-converting enzyme 2 (ACE2), the transmembrane protease serine 2 (TMPRSS2), and Neuropilin-1 (NRP1) on its surface. These structures are related to the mechanism of cell binding and invasion by SARS-COV-2, with the consequent inflammatory process and local destruction. As in other viral infections of the upper respiratory tract, the local severity of the infection can lead to more extensive lesions involving basal cells and reducing the regenerative capacity of the neuroepithelium. These lesions can lead to a partial replacement by metaplastic squamous epithelium. In Brazil, the first large survey on chemosensory dysfunctions pointed 82.4% general prevalence of smell impairment on COVID-19 infected patients.[2] A second study in the same country, pointed that there is no apparent difference in the prevalence of olfactory disorders between health professionals working on the front lines of combating the pandemic and the general population.[3] However, in the context of disease with significant clinical variability, publications regarding prevalence diverged, pointing from 5.1% to 98% in different parts of the world.[2] [4]. There is just one study showing a short prevalence of olfactory loss during the acute phase of COVID-19. All the other papers agree that this prevalence is high-ranging from 51% to up to 98%.[5] Multiple factors are listed as responsible for this variability, but two mechanisms are more commonly accepted and may manifest themselves individually or together: Fortunately, the recovery of quantitative olfactory disorders seems to occur spontaneously in a very high proportion of patients within two months, reducing the chance of its occurrence over time. On the other hand, qualitative disorders, such as parosmia and phantosmia, seem to start late and persist for a more extended time.[6] A Boscolo-Rizzo et al. cohort study showed a 43% prevalence of parosmia, with an average onset after 2.5 months and persistence of the complaint, without any improvement, of 40.6% after 6 months from the COVID-19 initiation.[7] The olfactory afferent pathway has complex relationships with different areas of the central nervous system. Therefore, a hypothesis regarding the association between a permanent loss of olfaction and taste known as chemosensory loss and neuropsychiatric disorders has been raised latterly. These correlated pathways might explain at least in part the possible association between olfactory dysfunctions and depressive symptoms raised by several previous studies. One small sample size study investigated the association between olfactory and taste dysfunction and psychiatric symptoms during COVID-19 pandemic. Authors found a positive correlation between severities of smell and taste loss, depression, and anxiety in a sample of COVID-19 survivors.[8] [9] However, there is no information regarding cognitive impairment and chemosensory disorders. Studies on the association of chemosensory loss and cognitive functions evaluated by dimensional and structured questionnaires are welcome. Several medications have been suggested to treat olfactory disorders, such as α-lipoic acid, omega-3, and sodium citrate. However, they still lack robust evidence to support their recommendation. A therapy that presents a tremendous biological plausibility is topical corticosteroids in high-volume washes or even orally. The suggested use must occur soon after polymerase chain reaction (PCR) negative in the rhinopharynx, aiming to reduce the inflammatory process and avoid the olfactory neuroepithelium's destruction. In a recent publication by an Italian group, a supplement composed of Palmitoylethanolamide (PEA) and Luteolin has shown anti-inflammatory effects. Like steroids, it has also been considered promising in olfactory recovery.[10] Olfactory training therapy can be beneficial both in the acute phase as in patients with chronic olfactory impairment, betting on the plasticity of the neural circuit as a route to at least partial recovery of the olfactory function. One of the methodological limitations in investigating treatments for olfaction recovery is the spontaneous character of recovery from the disease. Therefore, to prove that a difference between the intervention and control groups did not occur by chance, it is necessary to either have a large magnitude of effect or a large number of patients. However, up to date, very few randomized clinical trials have been published, all with a limited number of patients after infection by COVID-19. Article published online: 29 October 2021 © 2021....
- 29 October 2021
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 25 (04) , e479-e480
Open AccessCOVID-19 and Anosmia: Remaining Gaps to Knowledge
Since the emergence of the first cases of Sars-Cov-2 infection in November 2019, more than 224 million people have tested positive for COVID-19, and of these, more than 4.6 million have lost their lives worldwide.[1] Despite the rapid development of several types of vaccines that allowed a decrease in the rise of the number of new cases and deaths, the end of this story does not seem so close since fully vaccinated patients can also be infected. The virus has undergone constant mutations that sometimes produce milder symptoms and less resistance, sometimes manifest themselves more aggressively and with greater transmissibility. The olfactory disturbances in COVID-19 patients have drawn worldwide attention to an extremely important and often neglected sense. Smell plays a fundamental role in our lives, both for safety reasons as detecting odors of burning, gas leak or spoiled food, as well as in the quality of life by providing us with pleasure while eating, in interpersonal relationships, and also preventing us from hygiene issues. Despite the fact that there is no consensus regarding the exact pathophysiological mechanism, prevalence, and recovery of olfactory disorders in COVID-19, there is still a lot to understand about the persistent changes and how to intervene for adequate recovery of these patients. The olfactory neuroepithelium expresses receptors for the angiotensin-converting enzyme 2 (ACE2), the transmembrane protease serine 2 (TMPRSS2), and Neuropilin-1 (NRP1) on its surface. These structures are related to the mechanism of cell binding and invasion by SARS-COV-2, with the consequent inflammatory process and local destruction. As in other viral infections of the upper respiratory tract, the local severity of the infection can lead to more extensive lesions involving basal cells and reducing the regenerative capacity of the neuroepithelium. These lesions can lead to a partial replacement by metaplastic squamous epithelium. In Brazil, the first large survey on chemosensory dysfunctions pointed 82.4% general prevalence of smell impairment on COVID-19 infected patients.[2] A second study in the same country, pointed that there is no apparent difference in the prevalence of olfactory disorders between health professionals working on the front lines of combating the pandemic and the general population.[3] However, in the context of disease with significant clinical variability, publications regarding prevalence diverged, pointing from 5.1% to 98% in different parts of the world.[2] [4]. There is just one study showing a short prevalence of olfactory loss during the acute phase of COVID-19. All the other papers agree that this prevalence is high-ranging from 51% to up to 98%.[5] Multiple factors are listed as responsible for this variability, but two mechanisms are more commonly accepted and may manifest themselves individually or together: Fortunately, the recovery of quantitative olfactory disorders seems to occur spontaneously in a very high proportion of patients within two months, reducing the chance of its occurrence over time. On the other hand, qualitative disorders, such as parosmia and phantosmia, seem to start late and persist for a more extended time.[6] A Boscolo-Rizzo et al. cohort study showed a 43% prevalence of parosmia, with an average onset after 2.5 months and persistence of the complaint, without any improvement, of 40.6% after 6 months from the COVID-19 initiation.[7] The olfactory afferent pathway has complex relationships with different areas of the central nervous system. Therefore, a hypothesis regarding the association between a permanent loss of olfaction and taste known as chemosensory loss and neuropsychiatric disorders has been raised latterly. These correlated pathways might explain at least in part the possible association between olfactory dysfunctions and depressive symptoms raised by several previous studies. One small sample size study investigated the association between olfactory and taste dysfunction and psychiatric symptoms during COVID-19 pandemic. Authors found a positive correlation between severities of smell and taste loss, depression, and anxiety in a sample of COVID-19 survivors.[8] [9] However, there is no information regarding cognitive impairment and chemosensory disorders. Studies on the association of chemosensory loss and cognitive functions evaluated by dimensional and structured questionnaires are welcome. Several medications have been suggested to treat olfactory disorders, such as α-lipoic acid, omega-3, and sodium citrate. However, they still lack robust evidence to support their recommendation. A therapy that presents a tremendous biological plausibility is topical corticosteroids in high-volume washes or even orally. The suggested use must occur soon after polymerase chain reaction (PCR) negative in the rhinopharynx, aiming to reduce the inflammatory process and avoid the olfactory neuroepithelium's destruction. In a recent publication by an Italian group, a supplement composed of Palmitoylethanolamide (PEA) and Luteolin has shown anti-inflammatory effects. Like steroids, it has also been considered promising in olfactory recovery.[10] Olfactory training therapy can be beneficial both in the acute phase as in patients with chronic olfactory impairment, betting on the plasticity of the neural circuit as a route to at least partial recovery of the olfactory function. One of the methodological limitations in investigating treatments for olfaction recovery is the spontaneous character of recovery from the disease. Therefore, to prove that a difference between the intervention and control groups did not occur by chance, it is necessary to either have a large magnitude of effect or a large number of patients. However, up to date, very few randomized clinical trials have been published, all with a limited number of patients after infection by COVID-19. Article published online: 29 October 2021 © 2021....
- 1 January 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 87 (1) , 80-84
Papiloma invertido nasossinusal: taxa de recorrência e transformação maligna em 44 pacientes operados
- 1 January 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 87 (1) , 80-84
Papiloma invertido nasossinusal: taxa de recorrência e transformação maligna em 44 pacientes operados
- Open Access
- 1 September 2020
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 164 (3) , 512-518
Chemosensory Dysfunction in COVID‐19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample
Objective: Our study aimed to measure the percentage of reported olfactory or taste losses and their severity, recovery time, and association with other features in a large cohort of patients with COVID‐19.Study Design: Prospective survey.Setting: Quaternary medical center and online survey.Methods: The perceived chemosensory capacities of 655 patients with confirmed COVID‐19 were assessed with 11‐point category rating scales (0, no function; 10, normal function). Patients were contacted in hospital, by phone calls, or by internet regarding their ability to smell or taste, and 143 were interviewed by phone 1 to 4 months later to assess the recovery of their chemosensory abilities.Results: The prevalence of self‐reported olfactory, general taste, and taste quality–specific disturbances (sweet, sour, bitter, and salty) in the patients with COVID‐19 were 82.4% (95% CI, 79.5%‐85.3%), 76.2% (95% CI, 72.9%‐79.4%), and 52.2% (95% CI, 48.3%‐56.1%), respectively. The majority reported anosmia (42.9%). The presence of chemosensory symptoms was not associated with COVID‐19 severity. At a median time >2 months after the onset of symptoms, rates of total and partial olfaction recovery were 53.8% and 44.7%, while complete or partial return to previous taste function was 68.3% and 27.6%. Less than 5% of the patients reported no chemosensory function improvement at all.Conclusion: The prevalence of self‐reported chemosensory dysfunction is high among patients with COVID‐19. Almost all patients seem to recover a significant part of their smell and taste abilities in the first 4 months after the onset of symptoms.
- 1 September 2020
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 164 (3) , 512-518
Open AccessChemosensory Dysfunction in COVID‐19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample
Objective: Our study aimed to measure the percentage of reported olfactory or taste losses and their severity, recovery time, and association with other features in a large cohort of patients with COVID‐19.Study Design: Prospective survey.Setting: Quaternary medical center and online survey.Methods: The perceived chemosensory capacities of 655 patients with confirmed COVID‐19 were assessed with 11‐point category rating scales (0, no function; 10, normal function). Patients were contacted in hospital, by phone calls, or by internet regarding their ability to smell or taste, and 143 were interviewed by phone 1 to 4 months later to assess the recovery of their chemosensory abilities.Results: The prevalence of self‐reported olfactory, general taste, and taste quality–specific disturbances (sweet, sour, bitter, and salty) in the patients with COVID‐19 were 82.4% (95% CI, 79.5%‐85.3%), 76.2% (95% CI, 72.9%‐79.4%), and 52.2% (95% CI, 48.3%‐56.1%), respectively. The majority reported anosmia (42.9%). The presence of chemosensory symptoms was not associated with COVID‐19 severity. At a median time >2 months after the onset of symptoms, rates of total and partial olfaction recovery were 53.8% and 44.7%, while complete or partial return to previous taste function was 68.3% and 27.6%. Less than 5% of the patients reported no chemosensory function improvement at all.Conclusion: The prevalence of self‐reported chemosensory dysfunction is high among patients with COVID‐19. Almost all patients seem to recover a significant part of their smell and taste abilities in the first 4 months after the onset of symptoms.
- Open Access
- 15 June 2020
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 24 (03) , e386-e387
Olfaction and COVID: The little we Know and what else we need to know
The coronavirus disease 2019 (COVID-19) is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world. This infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recently, there have been numerous reports in the media that anosmia occurs in patients who have contracted coronavirus disease 2019 (COVID-19) by exposure to the SARS-COV-02 virus. The COVID-19 is usually characterized by upper and lower airway symptoms, such as fever, cough, dyspnea, sputum production, myalgia, arthralgia, headache, diarrhea, rhinorrhea, and sore throat. However, the spread of the virus worldwide has shown atypical complaints, such as olfaction and gustatory dysfunction.[1] [2] [3] In Brazil, since February 25th, there have been more than 120,000 infected individuals and 8,000 deaths until the date the present letter was written on. Self-reported anosmia has also been quite common in our country. Nowadays, there are a myriad of literature citations emerging, from single case report to self-reported surveys, from all over the world on this matter. Subsequently, a few hypotheses have risen in the past months regarding these symptoms. Most of the studies have detected an olfactory loss prevalence higher than 60%.[2] One European multicentric survey has shown a prevalence of 85.6% of all the infected population. The same study showed that 78% of the patients have recovered in at least 8 days[3]. A methodology to decrease response bias from self-reported data is testing subjects and controls. A study from Iran tested 60 patients with COVID-19 and 60 controls with the University of Pennsylvania Smell Identification Test. They found that 98% of the patients reported some degree of olfactory deficit. Although it is hard to test large sample sizes, this manuscript depicts more precise information regarding the classification of the chemosensory loss.[2] More extensive sample sizes studies would have detected differences in subgroups that this article from the Middle East might have failed to do. Another study from Europe hypothesized that olfactory disturbances could be highly associated with mild or moderate cases, even with a small sample size.[3] However, there is a lack of evidence that this atypical symptom could serve as a predictor of severity. Many studies support a high rate of simultaneous taste impairments. This probably should be secondary to the neuroepithelium damage. Survey studies usually have a trend to overestimate prevalence. However, most of them agree that the prevalence of olfactory loss is higher than 60% of cases.[1] [2] [3] [4] Future studies should clarify whether this chemosensory loss differs according to COVID-19 severity or hospitalized and non-hospitalized patients. It is important to emphasize that survey studies, even when using smell validated tests, usually overestimate prevalence, since subjects with anosmia or hyposmia tend to participate more in these studies. It is also not known if the recovery rate prevalence or duration varies in different countries where olfaction habits may vary. Although the association between olfaction and other nasal symptoms is not established, there is a weak association among microsmia, nasal obstruction, and rhinorrhea in this subset of patients.[3] [4] Another critical topic to be verified is if reporting loss of smell could be a reliable predictor to mild or moderate COVID-19 infection.[1] [2] Small-size surveys could fail to detect differences in subgroups, such as presence of asthma, chronic nasal symptoms, gender, and age groups. Larger sample size and well-defined strata would be the main features of the subsequent studies. All the data collected from observational studies could help us to better understand this pandemic disease. Regarding pathophysiology, the severe inflammation due to virus infection still needs better understanding, and maybe autopsies of patients who died could compare tissue damage between the olfactory epithelium and the bulb. In addition, the olfactory epithelium expresses two host receptors, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) proteases, that facilitate SARS COV 2 binding, replication, and accumulation. This may be the underlying mechanism for reported cases of smell dysfunction in patients with COVID 19. It is very likely that these receptors' neurons initiate the severe inflammation.[6] As a matter of fact, histopathological analysis, including harvesting cadaveric specimen from both olfactory epithelium and bulb, will help us understand the exact virus pathway. Finally, randomized clinical trials should also bring information on therapeutic alternatives, such as topical drugs, oral corticosteroids, and olfactory training.
- 15 June 2020
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 24 (03) , e386-e387
Open AccessOlfaction and COVID: The little we Know and what else we need to know
The coronavirus disease 2019 (COVID-19) is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world. This infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recently, there have been numerous reports in the media that anosmia occurs in patients who have contracted coronavirus disease 2019 (COVID-19) by exposure to the SARS-COV-02 virus. The COVID-19 is usually characterized by upper and lower airway symptoms, such as fever, cough, dyspnea, sputum production, myalgia, arthralgia, headache, diarrhea, rhinorrhea, and sore throat. However, the spread of the virus worldwide has shown atypical complaints, such as olfaction and gustatory dysfunction.[1] [2] [3] In Brazil, since February 25th, there have been more than 120,000 infected individuals and 8,000 deaths until the date the present letter was written on. Self-reported anosmia has also been quite common in our country. Nowadays, there are a myriad of literature citations emerging, from single case report to self-reported surveys, from all over the world on this matter. Subsequently, a few hypotheses have risen in the past months regarding these symptoms. Most of the studies have detected an olfactory loss prevalence higher than 60%.[2] One European multicentric survey has shown a prevalence of 85.6% of all the infected population. The same study showed that 78% of the patients have recovered in at least 8 days[3]. A methodology to decrease response bias from self-reported data is testing subjects and controls. A study from Iran tested 60 patients with COVID-19 and 60 controls with the University of Pennsylvania Smell Identification Test. They found that 98% of the patients reported some degree of olfactory deficit. Although it is hard to test large sample sizes, this manuscript depicts more precise information regarding the classification of the chemosensory loss.[2] More extensive sample sizes studies would have detected differences in subgroups that this article from the Middle East might have failed to do. Another study from Europe hypothesized that olfactory disturbances could be highly associated with mild or moderate cases, even with a small sample size.[3] However, there is a lack of evidence that this atypical symptom could serve as a predictor of severity. Many studies support a high rate of simultaneous taste impairments. This probably should be secondary to the neuroepithelium damage. Survey studies usually have a trend to overestimate prevalence. However, most of them agree that the prevalence of olfactory loss is higher than 60% of cases.[1] [2] [3] [4] Future studies should clarify whether this chemosensory loss differs according to COVID-19 severity or hospitalized and non-hospitalized patients. It is important to emphasize that survey studies, even when using smell validated tests, usually overestimate prevalence, since subjects with anosmia or hyposmia tend to participate more in these studies. It is also not known if the recovery rate prevalence or duration varies in different countries where olfaction habits may vary. Although the association between olfaction and other nasal symptoms is not established, there is a weak association among microsmia, nasal obstruction, and rhinorrhea in this subset of patients.[3] [4] Another critical topic to be verified is if reporting loss of smell could be a reliable predictor to mild or moderate COVID-19 infection.[1] [2] Small-size surveys could fail to detect differences in subgroups, such as presence of asthma, chronic nasal symptoms, gender, and age groups. Larger sample size and well-defined strata would be the main features of the subsequent studies. All the data collected from observational studies could help us to better understand this pandemic disease. Regarding pathophysiology, the severe inflammation due to virus infection still needs better understanding, and maybe autopsies of patients who died could compare tissue damage between the olfactory epithelium and the bulb. In addition, the olfactory epithelium expresses two host receptors, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) proteases, that facilitate SARS COV 2 binding, replication, and accumulation. This may be the underlying mechanism for reported cases of smell dysfunction in patients with COVID 19. It is very likely that these receptors' neurons initiate the severe inflammation.[6] As a matter of fact, histopathological analysis, including harvesting cadaveric specimen from both olfactory epithelium and bulb, will help us understand the exact virus pathway. Finally, randomized clinical trials should also bring information on therapeutic alternatives, such as topical drugs, oral corticosteroids, and olfactory training.
- Open Access
- 12 August 2019
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 87 (1) , 80-84
Sinonasal inverted papilloma: rate of recurrence and malignant transformation in 44 operated patients
- 12 August 2019
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 87 (1) , 80-84
Open AccessSinonasal inverted papilloma: rate of recurrence and malignant transformation in 44 operated patients
- Open Access
- 24 October 2018
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 23 (01) , 088-091
Mucocele: Clinical Characteristics and Outcomes in 46 Operated Patients
Introduction Paranasal sinus mucocele is a benign, expansive lesion associated with paranasal sinus obstruction. It affects mostly adults, and is most common in the frontal and ethmoidal sinuses. Objective To evaluate outcomes in patients undergoing surgical treatment for paranasal sinus mucocele. Methods Retrospective review of medical records of patients treated for paranasal sinus mucocele at the ENT department of a tertiary care hospital between 2005 and 2016. Results Forty-six patients underwent surgical treatment of paranasal sinus mucocele. The mean age was 50.1 years, and 56.5% were male. The most prevalent symptom was pain, and the frontal sinus was most commonly affected. The vast majority of patients (89.1%) underwent endoscopic sinus marsupialization; 10.9% required combined open and endoscopic access. Seven recurrences occurred. Conclusion Sinus mucocele is an expansive disease that primarily affects the frontal sinus of adult patients. In most cases, endoscopic surgery is an effective treatment modality.
- 24 October 2018
- Published by Georg Thieme Verlag KG in International Archives of Otorhinolaryngology
- Vol. 23 (01) , 088-091
Open AccessMucocele: Clinical Characteristics and Outcomes in 46 Operated Patients
Introduction Paranasal sinus mucocele is a benign, expansive lesion associated with paranasal sinus obstruction. It affects mostly adults, and is most common in the frontal and ethmoidal sinuses. Objective To evaluate outcomes in patients undergoing surgical treatment for paranasal sinus mucocele. Methods Retrospective review of medical records of patients treated for paranasal sinus mucocele at the ENT department of a tertiary care hospital between 2005 and 2016. Results Forty-six patients underwent surgical treatment of paranasal sinus mucocele. The mean age was 50.1 years, and 56.5% were male. The most prevalent symptom was pain, and the frontal sinus was most commonly affected. The vast majority of patients (89.1%) underwent endoscopic sinus marsupialization; 10.9% required combined open and endoscopic access. Seven recurrences occurred. Conclusion Sinus mucocele is an expansive disease that primarily affects the frontal sinus of adult patients. In most cases, endoscopic surgery is an effective treatment modality.